Capecitabine-Based Chemoendocrine Combination as First-Line Treatment for Metastatic Hormone-Positive Metastatic Breast Cancer: Phase 2 Study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Capecitabine-Based Chemoendocrine Combination as First-Line Treatment for Metastatic Hormone-Positive Metastatic Breast Cancer: Phase 2 Study

Published:2020-06 Issue:3 Volume:20 Page:228-237
ISSN:1526-8209
Container-title:Clinical Breast Cancer
language:en
Short-container-title:Clinical Breast Cancer

Author:

Rashad Noha^ORCID,Abdelhamid Thoraya,Shouman Samia A.,Nassar Hanan,Omran Mervat A.^ORCID,El Desouky Eman D.,Khaled Hussein

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference39 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin,2018

2. Global surveillance of cancer survival 1995-2009: Analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2);Allemani;Lancet,2015

3. Strategies for subtypes—dealing with the diversity of breast cancer. Highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2011;Goldhirsch;Ann Oncol,2011

4. Breast cancer subtypes and the risk of distant metastasis at initial diagnosis: a population-based study;Xiao;Cancer Manag Res,2018

5. Breast cancer;Hondermarck;Mol Cell Proteomics,2003

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Wise and skillful utilization of contemporary endocrine therapies for the treatment of ER+/HER2– advanced breast cancer;Oncology in Clinical Practice;2024-08-21

2. Combination of chemotherapy and endocrine treatment in breast cancer — is it still a taboo?;Oncology in Clinical Practice;2024-08-21

3. Combination of metronomic capecitabine and letrozole in metastatic hormone receptor positive, HER2 negative breast cancer: a randomized phase II trial;Journal of Chemotherapy;2024-05-20

4. Chemotherapy combined with endocrine neoadjuvant therapy for hormone receptor-positive local advanced breast cancer: a case report and literature review;Frontiers in Endocrinology;2024-03-13

5. Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer;Current Oncology;2023-06-24

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3